Craig M. Crews

Shoes For Crews® to Provide DEWALT® Industrial Products in Canada

Retrieved on: 
Tuesday, January 25, 2022
Multimedia, Craig M. Crews, Safety, Shoe, Partnership, BOCA, CSA, Shoemaking

BOCA RATON, Fla., Jan. 25, 2022 /PRNewswire/ --Shoes For Crews, the global leader in slip-resistant footwear since 1984, announced they have entered a new partnership agreement with DEWALT, providing an exclusive industrial footwear and apparel distributor in Canada.

Key Points: 
  • BOCA RATON, Fla., Jan. 25, 2022 /PRNewswire/ --Shoes For Crews, the global leader in slip-resistant footwear since 1984, announced they have entered a new partnership agreement with DEWALT, providing an exclusive industrial footwear and apparel distributor in Canada.
  • As safety footwear experts, it's a natural fit for Shoes For Crews to represent the DEWALTbrand in Canada.
  • To learn more about how to acquire DEWALTproducts for your employees, connect here with Dan Rubinstein, Director of Sales for Canada at Shoes For Crews.
  • Headquartered inBoca Raton, Florida, Shoes For Crews began producing slip-resistant footwear in 1984 with a mission to create a safer workplace.

The University of Tokyo and Eisai Announce Research Collaboration for the Development and Drug Discovery of Targeted Protein Degradation Technology

Retrieved on: 
Thursday, October 8, 2020
Branches of biology, Proteins, Biology, Eisai, Proteasome, Ubiquitin, Proteasome accessory factor E, Craig M. Crews

TOKYO, Oct 8, 2020 - (JCN Newswire) - The University of Tokyo and Eisai Co., Ltd. announced today a collaboration aiming for the development and drug discovery of targeted protein degradation technology has been created, with the establishment of a social cooperation program, "Protein Degradation Drug Discovery".

Key Points: 
  • TOKYO, Oct 8, 2020 - (JCN Newswire) - The University of Tokyo and Eisai Co., Ltd. announced today a collaboration aiming for the development and drug discovery of targeted protein degradation technology has been created, with the establishment of a social cooperation program, "Protein Degradation Drug Discovery".
  • The "Protein Degradation Drug Discovery" course is to be established within the Graduate School of Pharmaceutical Sciences, the University of Tokyo.
  • This research will combine the world's most advanced ubiquitin-proteasome research as conducted in the graduate school with drug discovery knowledge fostered by Eisai, for the development of new protein degradation technology towards proteins targeted by drugs and the promotion of drug discovery research based on this technology.
  • Through the development of this technology and drug discovery, the University of Tokyo and Eisai aim to provide new treatment options to patients for which treatment options were previously limited.

Arvinas Selects Certara to Advance Speed and Efficiency of Its Targeted Protein Degradation Research

Retrieved on: 
Monday, February 10, 2020
Technology, FDA, Hospitals, Software, Biotechnology, Networks, Health, Pharmaceutical, Data management, Branches of biology, Biology, Cell biology, Biotechnology, Pharmacology, Proteolysis targeting chimera, Metastatic breast cancer, Proteasome, Fusion protein, Craig M. Crews

Arvinas current drug discovery focus areas include metastatic prostate cancer, locally-advanced or metastatic breast cancer, and neurodegenerative diseases.

Key Points: 
  • Arvinas current drug discovery focus areas include metastatic prostate cancer, locally-advanced or metastatic breast cancer, and neurodegenerative diseases.
  • Arvinas is the pioneer and clinical-stage leader in the exciting new area of targeted protein degradation.
  • Its proprietary PROTAC (proteolysis-targeting chimera) protein degraders are chimeric, modular small molecules, which harness the bodys natural protein disposal system, the ubiquitinproteasome system, to induce the degradation of diseasecausing proteins.
  • Arvinas is employing Certaras D360 scientific informatics platform to increase the speed and efficiency of its lead identification and optimization processes.

Arvinas Strengthens Scientific Advisory Board with Leaders in Oncology and Neurological Disorders

Retrieved on: 
Wednesday, October 2, 2019
Craig M. Crews

Our scientific advisory board has been critical to the advancement of the Arvinas portfolio, and we believe the contributions of this talented group of advisors will be invaluable as we move forward.

Key Points: 
  • Our scientific advisory board has been critical to the advancement of the Arvinas portfolio, and we believe the contributions of this talented group of advisors will be invaluable as we move forward.
  • The Full Arvinas Scientific Advisory Board:
    Nearly 20 years ago, Dr. Craig Crews, Ph.D., began developing PROTAC protein degraders and is the pioneer in the field of targeted protein degradation.
  • brings deep knowledge and interest in oncology clinical trials and is an internationally renowned prostate cancer researcher and clinician.
  • He is also a Founder of Navire Pharma, Inc., and the Chair of its Scientific Advisory Board.

ESSA Pharma Enhances R&D Capabilities with Two New Key Hires

Retrieved on: 
Tuesday, April 24, 2018
Carfilzomib, Epoxides, Morpholines, Peptides, Moigne, Proteolix, Sanofi, Economy of France, Biotechnology, Chemistry, Raymond J. Deshaies, Craig M. Crews

Zhou and Le Moigne to ESSA," said David R. Parkinson, ESSA Pharma's President and Chief Executive Officer.

Key Points: 
  • Zhou and Le Moigne to ESSA," said David R. Parkinson, ESSA Pharma's President and Chief Executive Officer.
  • Prior to joining ESSA, he was Vice President of Chemistry at Cleave Biosciences, Group Leader at Proteolix and Scientist at Cytokinetics.
  • Over his career, he contributed to the discovery and development of KYPROLIS (carfilzomib), ONX0914 and omecamtiv mecarbil.
  • Prior to joining ESSA, he served as Senior Director of Pharmacology at Cleave Biosciences, and previously held scientific roles at Sanofi, where Dr.